This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Original article
Luo, Q. et al. An autonomous activation of interleukin-17 receptor signalling sustains inflammation and promotes disease progression. Immunity https://doi.org/10.1016/j.immuni.2023.06.012 (2023)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Flemming, A. Why do IL-17-targeted therapies have limited efficacy?. Nat Rev Immunol 23, 543 (2023). https://doi.org/10.1038/s41577-023-00930-5
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41577-023-00930-5